drugset / Trial / NCT00608075

Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder

NCT00608075

Phase 4 Unknown 260 enrolled University of Cincinnati
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of the research is to study brain structure, function and chemistry of patients with bipolar disorder who are receiving lithium, an FDA-approved treatment for bipolar mania, in order to better understand who benefits from treatment and why they respond to medications. Studying this may help improve treatment and outcome in patients with bipolar disorder.

Timeline

Start
2007-04
Primary completion
2015-07
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lithium Unknown 600 mg
Subject Lithium Unknown 1800 mg

Indications